Multiple Myeloma an incurable disease, but I have spent the last 25 years in remission using a blend of conventional oncology and evidence-based nutrition, supplementation, and lifestyle therapies from peer-reviewed studies that your oncologist probably hasn't told you about.
Click the orange button to the right to learn more about what you can start doing today.
Multiple Myeloma (MM) is considered incurable by conventional oncology. In other words, if an MM patient only pursues conventional MM therapies, he/she will experience remission, relapse, remission, relapse and finally, “there is nothing more that we can do for you.” That’s what happened to me anyway.
Therefore, in my opinion, MMers must think outside the conventional therapy box.
According to the study below Dichloroacetate (DCA) enhances the efficacy of Velcade. An MM patient can either make the standard dose of Velcade work better or reduce the standard dose possibly reducing the toxicity of Velcade and experiencing less toxicity aka fewer side effects.
Further, there are other non-conventional therapies, such as CBD oil and curcumin that have shown the ability to both kill mm cells as well as enhance the efficacy of Velcade.
I am both a long-term multiple myeloma survivor and myeloma cancer coach. I have remained in complete remission from my multiple myeloma since 1999 by living an evidence-based, non-toxic, anti-MM lifestyle through:
Please scroll down the page, post a question or a comment if you’d like to learn more about both conventional FDA approved MM therapies as well as evidence-based MM therapies.
Dichloroacetate (DCA), through the inhibition of aerobic glycolysis (the ‘Warburg effect’) and promotion of pyruvate oxidation, induces growth reduction in many tumors and is now undergoing several clinical trials. If aerobic glycolysis is active in multiple myeloma (MM) cells, it can be potentially targeted by DCA to induce myeloma growth inhibition.
Representative multiple myeloma cell lines and myeloma-bearing mice were treated with DCA, alone and in combination with bortezomib.
We found that aerobic glycolysis occurs in approximately half of MM cell lines examined, producing on average 1.86-fold more lactate than phorbol myristate acetate stimulated-peripheral blood mononuclear cells and is associated with low-oxidative capacity. Lower doses of DCA (5–10 mM) suppressed aerobic glycolysis and improved cellular respiration that was associated with activation of the pyruvate dehydrogenase complex. Higher doses of DCA (10–25 mM) induced superoxide production, apoptosis, suppressed proliferation with a G0/1and G2M phase arrest in MM cell lines. In addition, DCA increased MM cell line sensitivity to bortezomib, and combinatorial treatment of both agents improved the survival of myeloma-bearing mice.
Myeloma cells display aerobic glycolysis and DCA may complement clinically used MM therapies to inhibit disease progression.
“These findings and limited clinical results suggest that potentially fruitful areas for additional clinical trials include 1) adult and pediatric hhigh-gradeastrocytomas; 2) BRAF-mutant cancers, such as melanoma, perhaps combined with other pro-oxidants; 3) tumors in which resistance to standard platinum-class drugs alone may be overcome with combination therapy; and 4) tumors of endodermal origin, in which extensive experimental research has demonstrated significant anti-proliferative, pro-apoptotic effects of DCA, leading to improved host survival.”